Development and validation of a decision aid for choosing among antithrombotic agents for atrial fibrillation

Safoora Fatima1, Anne Holbrook2, Sam Schulman3

  • 1Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada.

Thrombosis Research
|July 9, 2016
PubMed

Insights

This study validated a decision aid for atrial fibrillation (AF) patients choosing antithrombotic agents. The tool improved patient confidence and knowledge regarding stroke prevention medications.

Area of Science:

  • Cardiology
  • Pharmacology
  • Health Informatics

Background:

  • Atrial fibrillation (AF) necessitates stroke prevention using various antithrombotic agents.
  • Patient decision-making can be complex due to multiple treatment options.
  • Decision aids can support informed choices for patients with AF.

Purpose of the Study:

  • To validate a decision aid for patients selecting antithrombotic therapies for AF.
  • To assess the aid's impact on patient confidence, knowledge, and understanding of treatment options.

Main Methods:

  • Prospective study involving patients aged 60 years or older.
  • Decision aid presented information on AF, aspirin, warfarin, and direct-acting oral anticoagulants (DOACs).
  • Primary outcome: decisional conflict; Secondary outcomes: knowledge, clarity, helpfulness, and comprehensiveness ratings.

Main Results:

  • Eighty-one patients participated; mean age 75.2 years.
  • Decision aid use resulted in low decisional conflict (7.2/100).
  • Significant improvement in knowledge scores (7.4 to 9.3/10) and high ratings for helpfulness, clarity, and comprehensiveness.

Conclusions:

  • The validated decision aid enhances patient participation in shared decision-making for AF anticoagulation.
  • Addresses a critical gap in medication safety for AF patients.
  • Further research needed to assess the impact of decision aids on clinical choices and outcomes.
Abstract

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
454
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
503
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
373
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
567
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.3K